Erlotinib-containing benzenesulfonamides as anti- agents through carbonic anhydrase inhibition.

Development of dual-acting antibacterial agents containing Erlotinib, a recognized EGFR inhibitor used as an anticancer agent, with differently spaced benzenesulfonamide moieties known to bind and inhibit carbonic anhydrase (CA) or the antiviral Zidovudine. Through rational design, ten derivatives were obtained via a straightforward synthesis including a click chemistry reaction. Inhibitory activity against a panel of pathogenic carbonic anhydrases and antibacterial susceptibility of ATCC 43504 were assessed.